Analytical Data
-
基因名
Siglec-3/CD33
- Application
-
别名
SIGLEC3; Gp67; p67; Myeloid cell surface antigen CD33
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P20138
-
表达区间
Asp18~His259
-
分子量
32kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-3, also known as CD33, is a sialic acid-binding immunoglobulin-like lectin predominantly expressed on the surface of myeloid cells, including monocytes and granulocytes. Its role in the immune system is significant, as it is involved in regulating cellular interactions and modulating immune responses. CD33 functions primarily as an inhibitory receptor, playing a crucial role in the negative regulation of immune activation. Elevated expression of CD33 has been associated with various hematological malignancies, particularly in acute myeloid leukemia (AML), where it serves as a potential therapeutic target. Research into recombinant CD33 proteins has gained momentum due to their potential utility in targeted therapies and drug delivery systems. By engineering CD33-based recombinant proteins, scientists aim to explore their ability to selectively bind to CD33-expressing cells, allowing for the development of novel immunotherapeutic approaches that can enhance the efficacy of existing treatments while minimizing side effects. Additionally, these studies aim to unravel the mechanistic insights behind CD33's role in immune modulation, and its involvement in tumor microenvironments. Overall, the investigation of Siglec-3/CD33 recombinant proteins holds promise in improving therapeutic strategies for cancer and other diseases linked to immune dysfunction, paving the way for innovative treatments that could lead to more effective patient outcomes.
